<DOC>
	<DOCNO>NCT01242254</DOCNO>
	<brief_summary>This study design assess efficacy safety multiple intravitreal injection KH902 patient CNV due AMD .</brief_summary>
	<brief_title>A Study Assessing Safety Efficacy Multiple Intravitreal KH902 Patients With CNV Due AMD</brief_title>
	<detailed_description>Due conclusion KH902 Ia study : Doses single intravitreal injection recombinant human VEGF receptor-Fc fusion protein ( KH902 ) patient CNV secondary neovascular AMD 0.05 mg 3.0 mg . The trial show KH902 safe tolerable , DLT , ophthalmia reaction , endophthalmitis , systemic AE relevant drug report , main AEs transient ocular tension increase micro-hemorrhage injection site . KH902 appear produce rapid clinical effect VA , support improvement anatomical feature , patient neovascular AMD . HOPE Study open label , multi-center , randomize , uncontrolled dose-and interval-ranging phase Ib study design assess efficacy safety multiple intravitreal injection KH902 variable dose regimen patient CNV due AMD . Two group patient initially receive intravitreal administration KH902 follow randomization : 1 . Patients group A receive monthly intravitreal injection KH902 3 time successively dose 0.5 mg/50 μl/eye ; 2 . Patients group B receive monthly intravitreal injection KH902 3 time successively dose 2.0 mg/50 μl/eye . Following initial 12-week fixed-dosing phase trial : Patients group A group B continue receive monthly intravitreal injection KH902 0.5 mg/50 μl/eye 2.0 mg/50 μl/eye dose he/she receive fixed dose phase , need ( PRN ) dose schedule , base upon need re-treatment accordance pre-specified criterion till week 52 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Signed Informed Consent Form patient legal representative ; Men woman ≥ 45 year age ; Active primary recurrent lesion CNV secondary neovascular AMD ; Total lesion size ≤ 12 disc area either eye ; BCVA study eye ＜ 69 letter BCVA fellow eye ≥ 19 letter ; Clear ocular medium adequate pupil dilation . CNV lesion secondary ocular condition neovascular AMD History vitreous hemorrhage , retinal tear , rhegmatogenous retinal detachment macular hole study eye ; Presence retinal detachment , retinal pigment epithelial tear , retinal macular traction study eye ; Anaphylactic disease ; Uncontrolled glaucoma either eye ; Current active ocular inflammation infection either eye ; Previous antiVEGF drug treatment study eye within three month precede screening , and/or , fellow eye , within one month precede screening ; Previous ophthalmologic operation laser therapy study eye within three month precede screening ; Current nonhealing wound , ulcer , fracture , etc ; Uncontrolled systemic condition ; Patients childbearing potential adopt adequate contraception method ; Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>KH902</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>multiple injection</keyword>
</DOC>